Stay updated on Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.

Latest updates to the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe NIH transition notice about using “Super Intelligence” instead of “Artificial Intelligence” has been removed from the top of the page.SummaryDifference1%

- Check18 days agoChange DetectedThe page has shifted from a 403 error screen to a mostly blank ClinicalTrials.gov page shell; the study record content is not visible.SummaryDifference0.6%

- Check25 days agoChange DetectedA banner announces an NIH website transition and says that “Super Intelligence” (SI) is being used in place of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe ClinicalTrials.gov error page footer now shows revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page for NCT04908189 now returns a 403 Forbidden page, replacing the previously visible trial details. The core content and study metadata that defined the record have been removed from the page in favor of the error screen.SummaryDifference19%

Stay in the know with updates to Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.